Biweekly peglated liposomal doxorubicin/oxaliplatin for ovarian cancer resistant to taxane-platinum treatment: A Phase II study

Salah-Eldin, Manal A.; Wahba, Hanan Ahmed; Halim, Amal

doi:10.4103/0019-509x.98944

Cited by 7 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In pretreated patients, OX combination with topotecan and liposomal doxorubicin yielded some encouraging results, showing 29% and 31.5% of responses, with a median PFS and OS of 5.5 to 7.3 and 10 to 15.5 months in mostly, though not exclusively, platinum resistant patients [34-37]. OX-based combinations with paclitaxel or fluorouracil appear promising in platinum resistant disease [38-40].…”

Section: Discussionmentioning

confidence: 99%

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients

Vici¹,

Sergi²,

Pizzuti³

et al. 2013

J Exp Clin Cancer Res

View full text Add to dashboard Cite

BackgroundCurrently, no clearly superior management strategy exists for recurrent, platinum-resistant ovarian cancer. We tested the efficacy and safety of gemcitabine combined with oxaliplatin (GEMOX) in a multicentre phase II clinical trial.MethodsForty one patients with recurrent, platinum-resistant ovarian cancer were enrolled. Prior to study entry, all the participants had received at least one platinum-based regimen. Gemcitabine was administered at 1000 mg/m2 as protracted infusion (100 min) on day 1, and oxaliplatin at the dose of 100 mg/m2 on day 2 in a 2 hour infusion. Cycles were repeated every two weeks.ResultsWe observed an overall response rate of 37% [95% Confidence Interval (CI), 22.3–51.7]. Objective responses plus disease stabilization (clinical benefit) occurred in 78% of patients. Median progression-free survival was 6.8 months (95% CI, 5.8–7.8), and median overall survival was 16.5 months (95% CI, 12.2–20.8). Median time to self-reported symptom relief, which was described by 22 out of 27 symptomatic patients (81.5%), was 4 weeks (range, 2–8). Grade 4 neutropenia and febrile neutropenia were observed in 2 (5%) and 1 (2.5%) patients, while grade 3 anemia was encountered in 2 (5%) patients, respectively. The most common adverse effects of any grade were gastrointestinal symptoms, fatigue and neutropenia. Nine patients (22%) experienced mild allergic reaction to oxaliplatin, with no treatment discontinuation.ConclusionsIn our cohort of recurrent, platinum-resistant ovarian cancer patients, GEMOX showed encouraging activity and manageable toxicity. Under circumstances requiring a rapid disease control, this combination regimen may offer a particularly viable option, particularly in heavily pretreated patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients

Vici¹,

Sergi²,

Pizzuti³

et al. 2013

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…Platinum-resistant disease was the setting of another Phase II study by Salah-Eldin aimed at evaluating the activity and toxicity of a biweekly schedule of pegylated liposomal doxorubicin plus oxaliplatin [54]. This regimen induced response or stable disease in 73.6% of the cases (28/38 patients) with acceptable side effects, no grade 4 toxicity and an OS of 10 months.…”

Section: Chemistrymentioning

confidence: 99%

Oxaliplatin for the treatment of ovarian cancer

Bogliolo

Cassani

Gardella

et al. 2015

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Platinum emerged as the mainstay of OC treatment in frontline therapy, and platinum compounds remain a critical component of chemotherapy also in relapsed disease. Unfortunately, increasing exposure to carboplatin/cisplatin raises the risk of resistance or hypersensitivity to platinum. Several studies have demonstrated the safety and effectiveness of oxaliplatin, both alone and in combination regimens, in relapsed OC, demonstrating a good tolerability profile. Moreover, the therapeutic spectrum of oxaliplatin might be extended to OC patients who experienced hypersensitivity to carboplatin because of its favorable toxicity profile and at least equal efficacy.

show abstract

“…A range of 16 -29% is the response rate of oxaliplatin as a single acting agent. 4,21,22 Clinical result reveals no significant renal or auditive toxicity with oxaliplatin in recommended dose but marginally hematotoxicity being noticed. Acute cold-triggered dysesthesias with parasethesia and cumulative neurosensorial toxicity is the major frequent side effects of oxaliplatin.…”

Section: Introductionmentioning

confidence: 91%

“…1,2 Approximately 225,000 women are diagnosed for ovarian cancer per year and there is record of almost 1, 40,000 deaths worldwide out of this disease. 3,4 Symptoms of the disease are not significant which may mimic other diseases conditions and cause delayed diagnosis. 5 The majority of the women about 75% are diagnosed with advanced stage diseases that are FIGO III or IV and overall survival rate for 5 years is about 40%.…”

Section: Introductionmentioning

confidence: 99%

“…3,11,12 Record reveals that approximately 75% of these patients attain complete clinical remission after the initial treatment. 4 Despite this fact, the majority of women with advanced EOC will ultimately relapse and 20% of these patients with platinum-and taxane-resistant disease. [13][14][15][16] Cases of recurrences within 6 months following an initial response to platinum-based treatment or patients with stable disease during Platinum-based therapy are recognized as having platinum-resistant EOC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The efficacy and safety of Oxaliplatin-Vinorelbine as a second-line chemotherapy combination in patients with platinum-resistant pretreated epithelial ovarian cancer: A retrospective study

Mumtahana

Tiang

Zhang

et al. 2014

Int J Cancer Ther Oncol

View full text Add to dashboard Cite

Purpose: The main purpose of this study was to analyze the effects and tolerability of Oxaliplatin-Vinorelbine combination on Platinum-resistant epithelial ovarian carcinoma (EOC) patients. Methods: A single centered retrospective study comprising of 34 patients was conducted, and all 34 patients were treated with Vinorelbine 30 mg/m 2 on day 1 and 8 along with Oxaliplatin 100 mg/m 2 on day 1 of 3 weeks treatment cycle following progressive platinum-resistant EOC. Results: The combination showed an overall response rate (ORR) of 18% (95% CI, 4.4-31.6) where 2 (6%) patients had complete response and 4 (12%) patients had partial response. Stable disease was observed in 9 (26%) patients and progressive disease in 19 (56%) patients. Median diseases free survival, median relapse free survival and median time to progression was 17.05 months, 4.4 months, and 1.25 months, respectively. Hematological toxicities were mild; only 1 (2.9%) patient had G3 anemia and major non-hematological toxicities include nausea-vomiting, diarrhea, constipation, hepatotoxicity, fatigueness and alopecia, which are mainly limited to G1-G2 and reversible. Conclusion: The effect of this combination is moderate as a second line treatment of platinum resistant EOC; however, in comparison with other regimens of Vinorelbine and Oxaliplatin, the activity is substandard but the toxicity profile is well tolerable. Further multicenter evaluation is needed for the better understanding of the therapeutic efficacy of the combination.

show abstract

Biweekly peglated liposomal doxorubicin/oxaliplatin for ovarian cancer resistant to taxane-platinum treatment: A Phase II study

Abstract: Biweekly PLD and L-OHP combination has high activity, with less than anticipated adverse toxicity, for treatment of platinum-resistant ovarian cancer. A comparison of the doublet PLD/L-OHP with single-agent treatment is warranted.

Cited by 7 publications

References 28 publications

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients

Oxaliplatin for the treatment of ovarian cancer

The efficacy and safety of Oxaliplatin-Vinorelbine as a second-line chemotherapy combination in patients with platinum-resistant pretreated epithelial ovarian cancer: A retrospective study

Contact Info

Product

Resources

About